-
1
-
-
74949139254
-
Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: A population-based study
-
Fernandez Perez ER, Daniels CE, Schroeder DR, St Sauver J, Hartman TE, Bartholmai BJ, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010; 137: 129-37.
-
(2010)
Chest
, vol.137
, pp. 129-137
-
-
Fernandez Perez, E.R.1
Daniels, C.E.2
Schroeder, D.R.3
St Sauver, J.4
Hartman, T.E.5
Bartholmai, B.J.6
-
2
-
-
20544443765
-
The clinical course of patients with idiopathic pulmonary fibrosis
-
Martinez FJ, Safrin S, Weycker D, Starko KM, Bradford WZ, King TE Jr, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005; 142(12 Pt 1): 963-7.
-
(2005)
Ann Intern Med.
, vol.142
, Issue.12
, pp. 963-967
-
-
Martinez, F.J.1
Safrin, S.2
Weycker, D.3
Starko, K.M.4
Bradford, W.Z.5
King, T.E.6
-
3
-
-
79952717349
-
An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management
-
Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011; 183: 788-824.
-
(2011)
Am J Respir Crit Care Med.
, vol.183
, pp. 788-824
-
-
Raghu, G.1
Collard, H.R.2
Egan, J.J.3
Martinez, F.J.4
Behr, J.5
Brown, K.K.6
-
4
-
-
85008987259
-
This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001
-
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002; 165: 277-304.
-
(2002)
Am J Respir Crit Care Med.
, vol.165
, pp. 277-304
-
-
-
6
-
-
77957229065
-
The registry of the international society for heart and lung transplantation: Twenty-seventh official adult lung and heart-lung transplant report-2010
-
Christie JD, Edwards LB, Kucheryavaya AY, Aurora P, Dobbels F, Kirk R, et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report-2010. J Heart Lung Transplant. 2010; 29: 1104-18.
-
(2010)
J Heart Lung Transplant.
, vol.29
, pp. 1104-1118
-
-
Christie, J.D.1
Edwards, L.B.2
Kucheryavaya, A.Y.3
Aurora, P.4
Dobbels, F.5
Kirk, R.6
-
8
-
-
0034011982
-
Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS)
-
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med. 2000; 161(2 Pt 1): 646-64.
-
(2000)
Am J Respir Crit Care Med.
, vol.161
, Issue.2
, pp. 646-664
-
-
-
9
-
-
79953728756
-
Novel therapeutic approaches for pulmonary fibrosis
-
Datta A, Scotton CJ, Chambers RC. Novel therapeutic approaches for pulmonary fibrosis. Br J Pharmacol. 2011; 163: 141-72.
-
(2011)
Br J Pharmacol.
, vol.163
, pp. 141-172
-
-
Datta, A.1
Scotton, C.J.2
Chambers, R.C.3
-
10
-
-
79951844263
-
Clinical course and prediction of survival in idiopathic pulmonary fibrosis
-
Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 183: 431-40.
-
(2011)
Am J Respir Crit Care Med.
, vol.183
, pp. 431-440
-
-
Ley, B.1
Collard, H.R.2
King, T.E.3
-
11
-
-
67650349068
-
Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): A multicentre, randomised, placebo-controlled trial
-
King TE Jr, Albera C, Bradford WZ, Costabel U, Hormel P, Lancaster L, et al. Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial. Lancet. 2009; 374: 222-8.
-
(2009)
Lancet
, vol.374
, pp. 222-228
-
-
King, T.E.1
Albera, C.2
Bradford, W.Z.3
Costabel, U.4
Hormel, P.5
Lancaster, L.6
-
13
-
-
77957957648
-
Non-steroid agents for idiopathic pulmonary fibrosis
-
Spagnolo P, Del Giovane C, Luppi F, Cerri S, Balduzzi S, Walters E H, et al. Non-steroid agents for idiopathic pulmonary fibrosis. Cochrane Database Syst Rev. 2010;(9): CD003134.
-
(2010)
Cochrane Database Syst Rev.
, Issue.9
, pp. CD003134
-
-
Spagnolo, P.1
Del Giovane, C.2
Luppi, F.3
Cerri, S.4
Balduzzi, S.5
Walters, E.H.6
-
14
-
-
0026389762
-
Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomized, placebocontrolled clinical trial
-
Raghu G, Depaso WJ, Cain K, Hammar SP, Wetzel CE, Dreis DF, et al. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebocontrolled clinical trial. Am Rev Respir Dis. 1991; 144: 291-6.
-
(1991)
Am Rev Respir Dis.
, vol.144
, pp. 291-296
-
-
Raghu, G.1
Depaso, W.J.2
Cain, K.3
Hammar, S.P.4
Wetzel, C.E.5
Dreis, D.F.6
-
15
-
-
84861394764
-
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis
-
Raghu G, Anstrom KJ, King TE Jr, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012; 366: 1968-77.
-
(2012)
N Engl J Med.
, vol.366
, pp. 1968-1977
-
-
Raghu, G.1
Anstrom, K.J.2
King, T.E.3
Lasky, J.A.4
Martinez, F.J.5
-
16
-
-
0029951895
-
Serum indicators of free radical activity in idiopathic pulmonary fibrosis
-
Jack CI, Jackson MJ, Johnston ID, Hind CR. Serum indicators of free radical activity in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1996; 153(6 Pt 1): 1918-23.
-
(1996)
Am J Respir Crit Care Med.
, vol.153
, Issue.6
, pp. 1918-1923
-
-
Jack, C.I.1
Jackson, M.J.2
Johnston, I.D.3
Hind, C.R.4
-
17
-
-
0031761169
-
8-isoprostane as a biomarker of oxidative stress in interstitial lung diseases
-
Montuschi P, Ciabattoni G, Paredi P, Pantelidis P, du Bois RM, Kharitonov SA, et al. 8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. Am J Respir Crit Care Med. 1998; 158 (5 Pt 1): 1524-7.
-
(1998)
Am J Respir Crit Care Med.
, vol.158
, Issue.5
, pp. 1524-1527
-
-
Montuschi, P.1
Ciabattoni, G.2
Paredi, P.3
Pantelidis, P.4
Du Bois, R.M.5
Kharitonov, S.A.6
-
18
-
-
0025886739
-
Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis
-
Borok Z, Buhl R, Grimes GJ, Bokser AD, Hubbard RC, Holroyd KJ, et al. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet. 1991; 338: 215-16.
-
(1991)
Lancet
, vol.338
, pp. 215-216
-
-
Borok, Z.1
Buhl, R.2
Grimes, G.J.3
Bokser, A.D.4
Hubbard, R.C.5
Holroyd, K.J.6
-
19
-
-
0036014536
-
Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: Effects of N-acetylcysteine
-
Behr J, Degenkolb B, Krombach F, Vogelmeier C. Intracellular glutathione and bronchoalveolar cells in fibrosing alveolitis: effects of N-acetylcysteine. Eur Respir J. 2002; 19: 906-11.
-
(2002)
Eur Respir J.
, vol.19
, pp. 906-911
-
-
Behr, J.1
Degenkolb, B.2
Krombach, F.3
Vogelmeier, C.4
-
20
-
-
28144459814
-
High-dose acetylcysteine in idiopathic pulmonary fibrosis
-
Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005; 353: 2229-42.
-
(2005)
N Engl J Med.
, vol.353
, pp. 2229-2242
-
-
Demedts, M.1
Behr, J.2
Buhl, R.3
Costabel, U.4
Dekhuijzen, R.5
Jansen, H.M.6
-
22
-
-
84901746607
-
Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis
-
Idiopathic Pulmonary Fibrosis Clinical Research Network; Martinez F J, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G, et al. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2093-101.
-
(2014)
N Engl J Med.
, vol.370
, pp. 2093-2101
-
-
Martinez, F.J.1
De Andrade, J.A.2
Anstrom, K.J.3
King, T.E.4
Raghu, G.5
-
23
-
-
0037338580
-
Interferon-gamma reduces interleukin-4- and interleukin-13-augmented transforming growth factor-beta2 production in human bronchial epithelial cells by targeting Smads
-
Wen FQ, Liu XD, Terasaki Y, Fang QH, Kobayashi T, Abe S, et al. Interferon-gamma reduces interleukin-4- and interleukin-13-augmented transforming growth factor-beta2 production in human bronchial epithelial cells by targeting Smads. Chest. 2003; 123(3 Suppl): 372S- 3S.
-
(2003)
Chest
, vol.123
, Issue.3
, pp. 372S-3S
-
-
Wen, F.Q.1
Liu, X.D.2
Terasaki, Y.3
Fang, Q.H.4
Kobayashi, T.5
Abe, S.6
-
24
-
-
0345824715
-
A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis
-
Raghu G, Brown KK, Bradford WZ, Starko K, Noble PW, Schwartz DA, et al. A placebo-controlled trial of interferon gamma-1b in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2004; 350: 125-33.
-
(2004)
N Engl J Med.
, vol.350
, pp. 125-133
-
-
Raghu, G.1
Brown, K.K.2
Bradford, W.Z.3
Starko, K.4
Noble, P.W.5
Schwartz, D.A.6
-
25
-
-
84859418092
-
Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis
-
Diaz KT, Skaria S, Harris K, Solomita M, Lau S, Bauer K, et al. Delivery and safety of inhaled interferon-gamma in idiopathic pulmonary fibrosis. J Aerosol Med Pulm Drug Deliv. 2012; 25: 79-87.
-
(2012)
J Aerosol Med Pulm Drug Deliv.
, vol.25
, pp. 79-87
-
-
Diaz, K.T.1
Skaria, S.2
Harris, K.3
Solomita, M.4
Lau, S.5
Bauer, K.6
-
26
-
-
0027213101
-
Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis
-
Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet. 1993; 341: 1550-4.
-
(1993)
Lancet
, vol.341
, pp. 1550-1554
-
-
Giaid, A.1
Michel, R.P.2
Stewart, D.J.3
Sheppard, M.4
Corrin, B.5
Hamid, Q.6
-
27
-
-
0023765634
-
Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells
-
Komuro I, Kurihara H, Sugiyama T, Yoshizumi M, Takaku F, Yazaki Y. Endothelin stimulates c-fos and c-myc expression and proliferation of vascular smooth muscle cells. FEBS Lett. 1988; 238: 249-52.
-
(1988)
FEBS Lett.
, vol.238
, pp. 249-252
-
-
Komuro, I.1
Kurihara, H.2
Sugiyama, T.3
Yoshizumi, M.4
Takaku, F.5
Yazaki, Y.6
-
28
-
-
0031629184
-
Endothelins: Effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts
-
Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM. Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts. J Cardiovasc Pharmacol. 1998; 31(Suppl 1): S360-3.
-
(1998)
J Cardiovasc Pharmacol.
, vol.31
, pp. S360-S363
-
-
Xu, S.1
Denton, C.P.2
Holmes, A.3
Dashwood, M.R.4
Abraham, D.J.5
Black, C.M.6
-
29
-
-
0032825924
-
Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases
-
Shahar I, Fireman E, Topilsky M, Grief J, Schwarz Y, Kivity S, et al. Effect of endothelin-1 on alpha-smooth muscle actin expression and on alveolar fibroblasts proliferation in interstitial lung diseases. Int J Immunopharmacol. 1999; 21: 759-75.
-
(1999)
Int J Immunopharmacol.
, vol.21
, pp. 759-775
-
-
Shahar, I.1
Fireman, E.2
Topilsky, M.3
Grief, J.4
Schwarz, Y.5
Kivity, S.6
-
30
-
-
0026954366
-
Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts
-
Peacock AJ, Dawes KE, Shock A, Gray AJ, Reeves JT, Laurent GJ. Endothelin-1 and endothelin-3 induce chemotaxis and replication of pulmonary artery fibroblasts. Am J Respir Cell Mol Biol. 1992; 7: 492-9.
-
(1992)
Am J Respir Cell Mol Biol.
, vol.7
, pp. 492-499
-
-
Peacock, A.J.1
Dawes, K.E.2
Shock, A.3
Gray, A.J.4
Reeves, J.T.5
Laurent, G.J.6
-
31
-
-
0030755489
-
Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist
-
Park SH, Saleh D, Giaid A, Michel RP. Increased endothelin-1 in bleomycin-induced pulmonary fibrosis and the effect of an endothelin receptor antagonist. Am J Respir Crit Care Med. 1997; 156(2 Pt 1): 600-8.
-
(1997)
Am J Respir Crit Care Med.
, vol.156
, Issue.2
, pp. 600-608
-
-
Park, S.H.1
Saleh, D.2
Giaid, A.3
Michel, R.P.4
-
32
-
-
37849012578
-
BUILD-1: A randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis
-
King TE Jr, Behr J, Brown KK, du Bois RM, Lancaster L, de Andrade JA, et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008; 177: 75-81.
-
(2008)
Am J Respir Crit Care Med.
, vol.177
, pp. 75-81
-
-
King, T.E.1
Behr, J.2
Brown, K.K.3
Du Bois, R.M.4
Lancaster, L.5
De Andrade, J.A.6
-
33
-
-
80051566676
-
BUILD-3: A randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis
-
King TE Jr, Brown KK, Raghu G, du Bois RM, Lynch DA, Martinez F, et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011; 184: 92-9.
-
(2011)
Am J Respir Crit Care Med.
, vol.184
, pp. 92-99
-
-
King, T.E.1
Brown, K.K.2
Raghu, G.3
Du Bois, R.M.4
Lynch, D.A.5
Martinez, F.6
-
34
-
-
53149152248
-
Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis
-
Nathan SD, Shlobin OA, Ahmad S, Koch J, Barnett SD, Ad N, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008; 76: 288-94.
-
(2008)
Respiration.
, vol.76
, pp. 288-294
-
-
Nathan, S.D.1
Shlobin, O.A.2
Ahmad, S.3
Koch, J.4
Barnett, S.D.5
Ad, N.6
-
35
-
-
58349114626
-
Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis
-
Glaser S, Noga O, Koch B, Opitz CF, Schmidt B, Temmesfeld B, et al. Impact of pulmonary hypertension on gas exchange and exercise capacity in patients with pulmonary fibrosis. Respir Med. 2009; 103: 317-24.
-
(2009)
Respir Med.
, vol.103
, pp. 317-324
-
-
Glaser, S.1
Noga, O.2
Koch, B.3
Opitz, C.F.4
Schmidt, B.5
Temmesfeld, B.6
-
36
-
-
33947386257
-
Sildenafil improves walk distance in idiopathic pulmonary fibrosis
-
Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007; 131: 897-9.
-
(2007)
Chest
, vol.131
, pp. 897-899
-
-
Collard, H.R.1
Anstrom, K.J.2
Schwarz, M.I.3
Zisman, D.A.4
-
37
-
-
0037152092
-
Sildenafil for treatment of lung fibrosis and pulmonary hypertension: A randomised controlled trial
-
Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet. 2002; 360: 895-900.
-
(2002)
Lancet
, vol.360
, pp. 895-900
-
-
Ghofrani, H.A.1
Wiedemann, R.2
Rose, F.3
Schermuly, R.T.4
Olschewski, H.5
Weissmann, N.6
-
38
-
-
77956640423
-
A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis
-
Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010; 363: 620-8.
-
(2010)
N Engl J Med.
, vol.363
, pp. 620-628
-
-
Zisman, D.A.1
Schwarz, M.2
Anstrom, K.J.3
Collard, H.R.4
Flaherty, K.R.5
Hunninghake, G.W.6
-
39
-
-
58149234456
-
Protein kinase inhibitors in the treatment of pulmonary fibrosis
-
Garneau-Tsodikova S, Thannickal VJ. Protein kinase inhibitors in the treatment of pulmonary fibrosis. Curr Med Chem. 2008; 15: 2632-40.
-
(2008)
Curr Med Chem.
, vol.15
, pp. 2632-2640
-
-
Garneau-Tsodikova, S.1
Thannickal, V.J.2
-
40
-
-
0028916492
-
Plateletderived growth factor isoforms PDGF-AA, -AB and -BB exert specific effects on collagen gene expression and mitotic activity of cultured human wound fibroblasts
-
Lepisto J, Peltonen J, Vaha-Kreula M, Niinikoski J, Laato M. Plateletderived growth factor isoforms PDGF-AA, -AB and -BB exert specific effects on collagen gene expression and mitotic activity of cultured human wound fibroblasts. Biochem Biophys Res Commun. 1995; 209: 393-9.
-
(1995)
Biochem Biophys Res Commun.
, vol.209
, pp. 393-399
-
-
Lepisto, J.1
Peltonen, J.2
Vaha-Kreula, M.3
Niinikoski, J.4
Laato, M.5
-
41
-
-
77749324295
-
Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results
-
Daniels C E, Lasky J A, Limper A H, Mieras K, Gabor E, Schroeder D R. Imatinib treatment for idiopathic pulmonary fibrosis: randomized placebo-controlled trial results. Am J Respir Crit Care Med. 2010; 181: 604-10.
-
(2010)
Am J Respir Crit Care Med.
, vol.181
, pp. 604-610
-
-
Daniels, C.E.1
Lasky, J.A.2
Limper, A.H.3
Mieras, K.4
Gabor, E.5
Schroeder, D.R.6
-
42
-
-
80053091084
-
Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis
-
Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011; 365: 1079-87.
-
(2011)
N Engl J Med.
, vol.365
, pp. 1079-1087
-
-
Richeldi, L.1
Costabel, U.2
Selman, M.3
Kim, D.S.4
Hansell, D.M.5
Nicholson, A.G.6
-
43
-
-
84901810710
-
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
-
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2071-82.
-
(2014)
N Engl J Med.
, vol.370
, pp. 2071-2082
-
-
Richeldi, L.1
Du Bois, R.M.2
Raghu, G.3
Azuma, A.4
Brown, K.K.5
Costabel, U.6
-
44
-
-
77958165170
-
Pirfenidone in idiopathic pulmonary fibrosis
-
Maher TM. Pirfenidone in idiopathic pulmonary fibrosis. Drugs Today (Barc). 2010; 46: 473-82.
-
(2010)
Drugs Today (Barc)
, vol.46
, pp. 473-482
-
-
Maher, T.M.1
-
45
-
-
0032842405
-
Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis
-
Iyer SN, Gurujeyalakshmi G, Giri SN. Effects of pirfenidone on transforming growth factor-beta gene expression at the transcriptional level in bleomycin hamster model of lung fibrosis. J Pharmacol Exp Ther. 1999; 291: 367-73.
-
(1999)
J Pharmacol Exp Ther.
, vol.291
, pp. 367-373
-
-
Iyer, S.N.1
Gurujeyalakshmi, G.2
Giri, S.N.3
-
46
-
-
48149113955
-
Antifibrotic action of pirfenidone and prednisolone: Different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis
-
Oku H, Shimizu T, Kawabata T, Nagira M, Hikita I, Ueyama A, et al. Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis. Eur J Pharmacol. 2008; 590: 400-8.
-
(2008)
Eur J Pharmacol.
, vol.590
, pp. 400-408
-
-
Oku, H.1
Shimizu, T.2
Kawabata, T.3
Nagira, M.4
Hikita, I.5
Ueyama, A.6
-
47
-
-
0036844834
-
Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production
-
Di Sario A, Bendia E, Svegliati Baroni G, Ridolfi F, Casini A, Ceni E, et al. Effect of pirfenidone on rat hepatic stellate cell proliferation and collagen production. J Hepatol. 2002; 37: 584-91.
-
(2002)
J Hepatol.
, vol.37
, pp. 584-591
-
-
Di Sario, A.1
Bendia, E.2
Svegliati Baroni, G.3
Ridolfi, F.4
Casini, A.5
Ceni, E.6
-
48
-
-
0032926937
-
Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: Results of a prospective, open-label Phase II study
-
Raghu G, Johnson WC, Lockhart D, Mageto Y. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, pirfenidone: results of a prospective, open-label Phase II study. Am J Respir Crit Care Med. 1999; 159(4 Pt 1): 1061-9.
-
(1999)
Am J Respir Crit Care Med.
, vol.159
, Issue.4
, pp. 1061-1069
-
-
Raghu, G.1
Johnson, W.C.2
Lockhart, D.3
Mageto, Y.4
-
49
-
-
20944434994
-
Doubleblind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis
-
Azuma A, Nukiwa T, Tsuboi E, Suga M, Abe S, Nakata K, et al. Doubleblind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2005; 171: 1040-7.
-
(2005)
Am J Respir Crit Care Med.
, vol.171
, pp. 1040-1047
-
-
Azuma, A.1
Nukiwa, T.2
Tsuboi, E.3
Suga, M.4
Abe, S.5
Nakata, K.6
-
50
-
-
77951160564
-
Pirfenidone in idiopathic pulmonary fibrosis
-
Taniguchi H, Ebina M, Kondoh Y, Ogura T, Azuma A, Suga M, et al. Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J. 2010; 35: 821-9.
-
(2010)
Eur Respir J.
, vol.35
, pp. 821-829
-
-
Taniguchi, H.1
Ebina, M.2
Kondoh, Y.3
Ogura, T.4
Azuma, A.5
Suga, M.6
-
51
-
-
79956341531
-
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): Two randomised trials
-
Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011; 377: 1760-9.
-
(2011)
Lancet
, vol.377
, pp. 1760-1769
-
-
Noble, P.W.1
Albera, C.2
Bradford, W.Z.3
Costabel, U.4
Glassberg, M.K.5
Kardatzke, D.6
-
52
-
-
84901759236
-
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
-
King T E J r, Bradford W Z, C astro-Bernardini S, Fagan E A, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014; 370: 2083-92.
-
(2014)
N Engl J Med.
, vol.370
, pp. 2083-2092
-
-
King, T.E.1
Bradford, W.Z.2
Astro-Bernardini, S.C.3
Fagan, E.A.4
Glaspole, I.5
Glassberg, M.K.6
-
53
-
-
84903166926
-
Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis
-
Valeyre D, Albera C, Bradford WZ, Costabel U, King TE Jr, Leff JA, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014; 19: 740-7.
-
(2014)
Respirology.
, vol.19
, pp. 740-747
-
-
Valeyre, D.1
Albera, C.2
Bradford, W.Z.3
Costabel, U.4
King, T.E.5
Leff, J.A.6
-
54
-
-
84900818404
-
Pirfenidone in idiopathic pulmonary fibrosis: Expert panel discussion on the management of drug-related adverse events
-
Costabel U, Bendstrup E, Cottin V, Dewint P, Egan JJ, Ferguson J, et al. Pirfenidone in idiopathic pulmonary fibrosis: expert panel discussion on the management of drug-related adverse events. Adv Ther. 2014; 31: 375-91.
-
(2014)
Adv Ther.
, vol.31
, pp. 375-391
-
-
Costabel, U.1
Bendstrup, E.2
Cottin, V.3
Dewint, P.4
Egan, J.J.5
Ferguson, J.6
-
55
-
-
0346096890
-
Angiotensin II and the fibroproliferative response to acute lung injury
-
Marshall RP, Gohlke P, Chambers RC, Howell DC, Bottoms SE, Unger T, et al. Angiotensin II and the fibroproliferative response to acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2004; 286: L156-64.
-
(2004)
Am J Physiol Lung Cell Mol Physiol.
, vol.286
, pp. L156-L164
-
-
Marshall, R.P.1
Gohlke, P.2
Chambers, R.C.3
Howell, D.C.4
Bottoms, S.E.5
Unger, T.6
-
56
-
-
34248355179
-
A ngiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: Autocrine mechanisms in myofibroblasts and macrophages
-
Uhal B D, Kim J K, Li X, M olina-Molina M. A ngiotensin-TGF-beta 1 crosstalk in human idiopathic pulmonary fibrosis: autocrine mechanisms in myofibroblasts and macrophages. Curr Pharm Des. 2007; 13: 1247-56.
-
(2007)
Curr Pharm Des.
, vol.13
, pp. 1247-1256
-
-
Uhal, B.D.1
Kim, J.K.2
Li, X.3
Olina-Molina, M.M.4
-
57
-
-
0033862955
-
Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor
-
Wang R, Ibarra-Sunga O, Verlinski L, Pick R, Uhal BD. Abrogation of bleomycin-induced epithelial apoptosis and lung fibrosis by captopril or by a caspase inhibitor. Am J Physiol Lung Cell Mol Physiol. 2000; 279: L143-51.
-
(2000)
Am J Physiol Lung Cell Mol Physiol.
, vol.279
, pp. L143-L151
-
-
Wang, R.1
Ibarra-Sunga, O.2
Verlinski, L.3
Pick, R.4
Uhal, B.D.5
-
58
-
-
0346057802
-
Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist
-
Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax. 2004; 59: 31-8.
-
(2004)
Thorax
, vol.59
, pp. 31-38
-
-
Otsuka, M.1
Takahashi, H.2
Shiratori, M.3
Chiba, H.4
Abe, S.5
-
59
-
-
33751077307
-
Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis
-
Li X, Molina-Molina M, Abdul-Hafez A, Ramirez J, Serrano-Mollar A, Xaubet A, et al. Extravascular sources of lung angiotensin peptide synthesis in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2006; 291: L887-95.
-
(2006)
Am J Physiol Lung Cell Mol Physiol.
, vol.291
, pp. L887-L895
-
-
Li, X.1
Molina-Molina, M.2
Abdul-Hafez, A.3
Ramirez, J.4
Serrano-Mollar, A.5
Xaubet, A.6
-
60
-
-
4143091523
-
Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis
-
Nadrous HF, Ryu JH, Douglas WW, Decker PA, Olson EJ. Impact of angiotensin-converting enzyme inhibitors and statins on survival in idiopathic pulmonary fibrosis. Chest. 2004; 126: 438-46.
-
(2004)
Chest
, vol.126
, pp. 438-446
-
-
Nadrous, H.F.1
Ryu, J.H.2
Douglas, W.W.3
Decker, P.A.4
Olson, E.J.5
-
61
-
-
40349098060
-
Procoagulant signalling mechanisms in lung inflammation and fibrosis: Novel opportunities for pharmacological intervention?
-
Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol. 2008; 153(Suppl 1): S367-78.
-
(2008)
Br J Pharmacol.
, vol.153
, pp. S367-S378
-
-
Chambers, R.C.1
-
62
-
-
0028835189
-
Role of thrombin in pulmonary fibrosis
-
Hernandez-Rodriguez NA, Cambrey AD, Harrison NK, Chambers RC, Gray AJ, Southcott AM, et al. Role of thrombin in pulmonary fibrosis. Lancet. 1995; 346: 1071-3.
-
(1995)
Lancet
, vol.346
, pp. 1071-1073
-
-
Hernandez-Rodriguez, N.A.1
Cambrey, A.D.2
Harrison, N.K.3
Chambers, R.C.4
Gray, A.J.5
Southcott, A.M.6
-
63
-
-
0034795622
-
Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis
-
Howell DC, Goldsack NR, Marshall RP, McAnulty RJ, Starke R, Purdy G, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol. 2001; 159: 1383-95.
-
(2001)
Am J Pathol.
, vol.159
, pp. 1383-1395
-
-
Howell, D.C.1
Goldsack, N.R.2
Marshall, R.P.3
McAnulty, R.J.4
Starke, R.5
Purdy, G.6
-
64
-
-
70349422341
-
Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury
-
Scotton C J, Krupiczojc M A, Konigshoff M, Mercer PF, Lee YC, Kaminski N, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest. 2009; 119: 2550-63.
-
(2009)
J Clin Invest.
, vol.119
, pp. 2550-2563
-
-
Scotton, C.J.1
Krupiczojc, M.A.2
Konigshoff, M.3
Mercer, P.F.4
Lee, Y.C.5
Kaminski, N.6
-
65
-
-
0344742226
-
Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits
-
Gunther A, Lubke N, Ermert M, Schermuly R T, Weissmann N, Breithecker A, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med. 2003; 168: 1358-65.
-
(2003)
Am J Respir Crit Care Med.
, vol.168
, pp. 1358-1365
-
-
Gunther, A.1
Lubke, N.2
Ermert, M.3
Schermuly, R.T.4
Weissmann, N.5
Breithecker, A.6
-
66
-
-
24944467299
-
Anticoagulant therapy for idiopathic pulmonary fibrosis
-
Kubo H, Nakayama K, Yanai M, Suzuki T, Yamaya M, Watanabe M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005; 128: 1475-82.
-
(2005)
Chest
, vol.128
, pp. 1475-1482
-
-
Kubo, H.1
Nakayama, K.2
Yanai, M.3
Suzuki, T.4
Yamaya, M.5
Watanabe, M.6
-
67
-
-
84863450246
-
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis
-
Noth I, Anstrom KJ, Calvert SB, de Andrade J, Flaherty KR, Glazer C, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012; 186: 88-95.
-
(2012)
Am J Respir Crit Care Med.
, vol.186
, pp. 88-95
-
-
Noth, I.1
Anstrom, K.J.2
Calvert, S.B.3
De Andrade, J.4
Flaherty, K.R.5
Glazer, C.6
-
68
-
-
0027231698
-
Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis
-
Nash JR, McLaughlin PJ, Butcher D, Corrin B. Expression of tumour necrosis factor-alpha in cryptogenic fibrosing alveolitis. Histopathology. 1993; 22: 343-7.
-
(1993)
Histopathology.
, vol.22
, pp. 343-347
-
-
Nash, J.R.1
McLaughlin, P.J.2
Butcher, D.3
Corrin, B.4
-
69
-
-
0027724235
-
Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis
-
Piguet PF, Ribaux C, Karpuz V, Grau GE, Kapanci Y. Expression and localization of tumor necrosis factor-alpha and its mRNA in idiopathic pulmonary fibrosis. Am J Pathol. 1993; 143: 651-5.
-
(1993)
Am J Pathol.
, vol.143
, pp. 651-655
-
-
Piguet, P.F.1
Ribaux, C.2
Karpuz, V.3
Grau, G.E.4
Kapanci, Y.5
-
70
-
-
0032084906
-
Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis
-
Ziegenhagen MW, Schrum S, Zissel G, Zipfel PF, Schlaak M, Muller-Quernheim J. Increased expression of proinflammatory chemokines in bronchoalveolar lavage cells of patients with progressing idiopathic pulmonary fibrosis and sarcoidosis. J Investig Med. 1998; 46: 223-31.
-
(1998)
J Investig Med.
, vol.46
, pp. 223-231
-
-
Ziegenhagen, M.W.1
Schrum, S.2
Zissel, G.3
Zipfel, P.F.4
Schlaak, M.5
Muller-Quernheim, J.6
-
71
-
-
0024414604
-
Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis
-
Piguet P F, Collart M A, Grau G E, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989; 170: 655-63.
-
(1989)
J Exp Med.
, vol.170
, pp. 655-663
-
-
Piguet, P.F.1
Collart, M.A.2
Grau, G.E.3
Kapanci, Y.4
Vassalli, P.5
-
72
-
-
0031568010
-
TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis
-
Zhang K, Gharaee-Kermani M, McGarry B, Remick D, Phan SH. TNF-alpha-mediated lung cytokine networking and eosinophil recruitment in pulmonary fibrosis. J Immunol. 1997; 158: 954-9.
-
(1997)
J Immunol.
, vol.158
, pp. 954-959
-
-
Zhang, K.1
Gharaee-Kermani, M.2
McGarry, B.3
Remick, D.4
Phan, S.H.5
-
73
-
-
7844226301
-
Expression of TNF and the necessity of TNF receptors in bleomycininduced lung injury in mice
-
Ortiz LA, Lasky J, Hamilton RF Jr, Holian A, Hoyle GW, Banks W, et al. Expression of TNF and the necessity of TNF receptors in bleomycininduced lung injury in mice. Exp Lung Res. 1998; 24: 721-43.
-
(1998)
Exp Lung Res.
, vol.24
, pp. 721-743
-
-
Ortiz, L.A.1
Lasky, J.2
Hamilton, R.F.3
Holian, A.4
Hoyle, G.W.5
Banks, W.6
-
74
-
-
36849013374
-
Soluble TNF mediates the transition from pulmonary inflammation to fibrosis
-
Oikonomou N, Harokopos V, Zalevsky J, Valavanis C, Kotanidou A, Szymkowski DE, et al. Soluble TNF mediates the transition from pulmonary inflammation to fibrosis. PLoS One. 2006; 1: e108.
-
(2006)
PLoS One
, vol.1
, pp. e108
-
-
Oikonomou, N.1
Harokopos, V.2
Zalevsky, J.3
Valavanis, C.4
Kotanidou, A.5
Szymkowski, D.E.6
-
75
-
-
0032813516
-
On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease
-
Kollias G, Douni E, Kassiotis G, Kontoyiannis D. On the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Immunol Rev. 1999; 169: 175-94.
-
(1999)
Immunol Rev.
, vol.169
, pp. 175-194
-
-
Kollias, G.1
Douni, E.2
Kassiotis, G.3
Kontoyiannis, D.4
-
76
-
-
55549147184
-
Treatment of idiopathic pulmonary fibrosis with etanercept: An exploratory, placebo-controlled trial
-
Raghu G, Brown KK, Costabel U, Cottin V, du Bois RM, Lasky JA, et al. Treatment of idiopathic pulmonary fibrosis with etanercept: an exploratory, placebo-controlled trial. Am J Respir Crit Care Med. 2008; 178: 948-55.
-
(2008)
Am J Respir Crit Care Med.
, vol.178
, pp. 948-955
-
-
Raghu, G.1
Brown, K.K.2
Costabel, U.3
Cottin, V.4
Du Bois, R.M.5
Lasky, J.A.6
-
77
-
-
34250872717
-
Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice
-
Tabata C, Tabata R, Kadokawa Y, Hisamori S, Takahashi M, Mishima M, et al. Thalidomide prevents bleomycin-induced pulmonary fibrosis in mice. J Immunol. 2007; 179: 708-14.
-
(2007)
J Immunol.
, vol.179
, pp. 708-714
-
-
Tabata, C.1
Tabata, R.2
Kadokawa, Y.3
Hisamori, S.4
Takahashi, M.5
Mishima, M.6
-
78
-
-
0032100486
-
Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset
-
Haslett PA, Corral LG, Albert M, Kaplan G. Thalidomide costimulates primary human T lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic responses in the CD8 + subset. J Exp Med. 1998; 187: 1885-92.
-
(1998)
J Exp Med.
, vol.187
, pp. 1885-1892
-
-
Haslett, P.A.1
Corral, L.G.2
Albert, M.3
Kaplan, G.4
-
80
-
-
84868327008
-
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: A randomized trial
-
Horton MR, Santopietro V, Mathew L, Horton KM, Polito AJ, Liu MC, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012; 157: 398-406.
-
(2012)
Ann Intern Med.
, vol.157
, pp. 398-406
-
-
Horton, M.R.1
Santopietro, V.2
Mathew, L.3
Horton, K.M.4
Polito, A.J.5
Liu, M.C.6
-
81
-
-
11144241299
-
Carbon monoxide suppresses bleomycin-induced lung fibrosis
-
Zhou Z, Song R, Fattman CL, Greenhill S, Alber S, Oury TD, et al. Carbon monoxide suppresses bleomycin-induced lung fibrosis. Am J Pathol. 2005; 166: 27-37.
-
(2005)
Am J Pathol.
, vol.166
, pp. 27-37
-
-
Zhou, Z.1
Song, R.2
Fattman, C.L.3
Greenhill, S.4
Alber, S.5
Oury, T.D.6
-
82
-
-
77956425361
-
Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment
-
Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat Med. 2010; 16: 1009-17.
-
(2010)
Nat Med.
, vol.16
, pp. 1009-1017
-
-
Barry-Hamilton, V.1
Spangler, R.2
Marshall, D.3
McCauley, S.4
Rodriguez, H.M.5
Oyasu, M.6
-
83
-
-
48949117336
-
Hyper-responsiveness of IPF/UIP fibroblasts: Interplay between TGFbeta1, IL-13 and CCL2
-
Murray LA, Argentieri RL, Farrell FX, Bracht M, Sheng H, Whitaker B, et al. Hyper-responsiveness of IPF/UIP fibroblasts: interplay between TGFbeta1, IL-13 and CCL2. Int J Biochem Cell Biol. 2008; 40: 2174-82.
-
(2008)
Int J Biochem Cell Biol.
, vol.40
, pp. 2174-2182
-
-
Murray, L.A.1
Argentieri, R.L.2
Farrell, F.X.3
Bracht, M.4
Sheng, H.5
Whitaker, B.6
-
84
-
-
79951713169
-
Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease
-
Wang Q, Usinger W, Nichols B, Gray J, Xu L, Seeley TW, et al. Cooperative interaction of CTGF and TGF-beta in animal models of fibrotic disease. Fibrogenesis Tissue Repair. 2011; 4: 4.
-
(2011)
Fibrogenesis Tissue Repair.
, vol.4
, pp. 4
-
-
Wang, Q.1
Usinger, W.2
Nichols, B.3
Gray, J.4
Xu, L.5
Seeley, T.W.6
-
85
-
-
84975326256
-
Phase 2 trial of FG-109, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): Preliminary safety and efficacy results
-
Raghu G, Scholand MB, de Andrade J, Lancaster L, Goldin MB, Porter S, et al. Phase 2 trial of FG-109, anti-CTGF monoclonal antibody, in idiopathic pulmonary fibrosis (IPF): preliminary safety and efficacy results. Eur Respir J. 2012; 40: Suppl. 56, 511s.
-
(2012)
Eur Respir J.
, vol.40
, pp. 511S
-
-
Raghu, G.1
Scholand, M.B.2
De Andrade, J.3
Lancaster, L.4
Goldin, M.B.5
Porter, S.6
-
86
-
-
84928126872
-
Predictors of mortality in idiopathic pulmonary fibrosis: Results from 72 week phase II study of CNTO888 (Carlumab)
-
Raghu G, Agarwal P, Mack M, Martinez F, Brown K, Costabel U, et al. Predictors of mortality in idiopathic pulmonary fibrosis: results from 72 week phase II study of CNTO888 (Carlumab). Am J Respir Crit Care Med. 2013; 187: A3377.
-
(2013)
Am J Respir Crit Care Med.
, vol.187
, pp. A3377
-
-
Raghu, G.1
Agarwal, P.2
MacK, M.3
Martinez, F.4
Brown, K.5
Costabel, U.6
-
87
-
-
0036840030
-
MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis
-
Yoshida K, Kuwano K, Hagimoto N, Watanabe K, Matsuba T, Fujita M, et al. MAP kinase activation and apoptosis in lung tissues from patients with idiopathic pulmonary fibrosis. J Pathol. 2002; 198: 388-96.
-
(2002)
J Pathol.
, vol.198
, pp. 388-396
-
-
Yoshida, K.1
Kuwano, K.2
Hagimoto, N.3
Watanabe, K.4
Matsuba, T.5
Fujita, M.6
-
88
-
-
2142646426
-
T GF-beta signaling and the fibrotic response
-
Leask A, Abraham D J. T GF-beta signaling and the fibrotic response. FASEB J. 2004; 18: 816-27.
-
(2004)
FASEB J.
, vol.18
, pp. 816-827
-
-
Leask, A.1
Abraham, D.J.2
-
89
-
-
38049002642
-
Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation
-
Horan GS, Wood S, Ona V, Li DJ, Lukashev ME, Weinreb PH, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med. 2008; 177: 56-65.
-
(2008)
Am J Respir Crit Care Med.
, vol.177
, pp. 56-65
-
-
Horan, G.S.1
Wood, S.2
Ona, V.3
Li, D.J.4
Lukashev, M.E.5
Weinreb, P.H.6
|